GLYC - グリコ・ミメティックス (GlycoMimetics Inc.)

GLYCのニュース

   GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020  2020/07/24 13:15:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020  2020/07/24 13:15:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Report First Quarter Financial Results on May 1, 2020  2020/04/24 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following t

calendar